Davis' comments on Tuesday echo those from January, when he said showing outcomes for cardiovascular, diabetes and conditions other than weight management would make it easier for drugs to get insurance reimbursements.
The weight-loss drug market is estimated to be worth about $150 billion in annual global sales by the early 2030s and is currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both belonging to the GLP-1 class.
GLP-1 drugs, which help slow digestion and reduce hunger by triggering a feeling of fullness, are now being studied to see whether they can improve health in other ways.
Merck said earlier this year that it was seeking GLP-1 treatments with benefits beyond weight loss as the drugmaker develops its own candidate, efinopegdutide, for a type of serious fatty liver disease now known as metabolic dysfunction-associated steatohepatitis (MASH).
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd